Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2011 15:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Presents Data on Retaspimycin Hydrochloride, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer at ASCO Meeting

CHICAGO, June 6, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from a Phase 1b trial of retaspimycin hydrochloride (HCl) (also known as...
June 04, 2011 09:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Reports Results From Phase 1b Clinical Trial of IPI-926, an Oral Smoothened Antagonist, in Pancreatic Cancer at ASCO Meeting

CHICAGO, June 4, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of IPI-926...
June 01, 2011 06:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Highlight Clinical Progress and Review Abstracts to be Presented at ASCO Annual Meeting

— Company to Host Webcast and Conference Call Today at 8:30 a.m. ET with Dr. Gregory Riely, Principal Investigator for Ongoing Phase 2 Trial of Retaspimycin HCl, a Novel...
May 31, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals to Present at Jefferies Conference

CAMBRIDGE, Mass., May 31, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at Jefferies Global Healthcare Conference on Wednesday, June 8, 2011 at 9:30 a.m. ET...
May 19, 2011 08:02 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Initiates Randomized Phase 2 Trial of IPI-504, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer

CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the initiation of a Phase 2 clinical trial of retaspimycin hydrochloride (HCl), also...
May 19, 2011 07:58 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Clinical Data to be Presented at ASCO

CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that clinical data for IPI-926, its novel Smoothened antagonist, and retaspimycin...
May 10, 2011 16:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Reports First Quarter 2011 Financial Results

— Reaffirms 2011 Financial Guidance and Provides Additional Details — — Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer...
May 03, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces the Date of Its First Quarter 2011 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., May 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, May 10, 2011 at 4:30 p.m. ET. During the call, management will...
April 11, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Appointment of Joshua Hamermesh as Vice President, Business and Corporate Development

CAMBRIDGE, Mass., April 11, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the appointment of Joshua D. Hamermesh as vice president, business and corporate...
April 07, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals to Present at BioCentury Future Leaders Conference

CAMBRIDGE, Mass., April 7, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at BioCentury's 18th Annual Future Leaders in the Biotech Industry Conference on...